Highlights

• PolyNovo gained 2.94% to $1.05 on 4 September 2026

• FY2026 annual reporting covers NovoSorb commercialisation and wound care expansion

• International commercial operations continue expanding across global markets

• FY2026 disclosures cover revenue, earnings, cash and geographic sales

PolyNovo Ltd (ASX:PNV) climbed 2.94% to $1.05 on 4 September 2026. The Melbourne-based wound care company, known for its NovoSorb biodegradable polymer technology, has been building a growing international commercial presence, and investor interest continues to track the pace of its global expansion in burns and complex wound care.

About the Company

PolyNovo is an Australian medical device company that has developed NovoSorb — a proprietary biodegradable polyurethane technology used to manufacture wound care products. The company's lead product, NovoSorb BTM (Biodegradable Temporising Matrix), is used in the management of full-thickness burns and complex wounds. PolyNovo has secured regulatory clearances across multiple jurisdictions and sells through its own direct sales force in the United States, United Kingdom, Europe and Australasia, with distribution partnerships in other regions.

Key Developments

PolyNovo's latest reporting covers FY2026 financial and operational performance, including continued commercialisation of its NovoSorb technology and wound-care products. The company continues expanding its international commercial operations and product portfolio. Its latest annual disclosures provide financial information covering revenue, earnings, cash resources, operating expenses and geographic sales across its global business.

Key Catalysts to Watch

• Revenue growth acceleration in the US market through direct sales expansion

• New product developments extending NovoSorb technology to adjacent wound indications

• Geographic market expansion into new international territories

• Progress toward sustained profitability as commercial scale is achieved

Risks

• Pre-profitability stage with ongoing cash burn from commercial operations

• Competition from established wound care companies including Smith & Nephew and Molnlycke

• Hospital and burn centre adoption cycles can be lengthy

• Currency exposure from international revenue across USD, GBP and EUR

Conclusion

PolyNovo's 2.94% gain on 4 September reflects sustained investor confidence in the NovoSorb growth story. The company has made meaningful progress in building a direct commercial presence in key markets, and the path toward profitability is becoming clearer as revenue scales. For investors willing to take on early-commercialisation risk in a genuine biomedical innovation, PNV offers an interesting long-term proposition. Watching quarterly revenue progression and cash burn trends will be key.